Substances · Cathinone derivatives
α-PHP
- Preferred name
- α-PHP
- IUPAC name
- 1-phenyl-2-pyrrolidin-1-ylhexan-1-one
- Parent CAS number (reference)
- 13415-86-6
- Molecular formula
- C16H23NO
- Molecular weight
- 245.36 g/mol
- InChIKey
- KYIJLDDXQWBNGX-UHFFFAOYSA-N
- PubChem
- CID 102107923
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
alpha-PHP a-PHP aPHP alpha-pyrrolidinohexiophenone PV-7
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
alpha-PHP (alpha-Pyrrolidinohexiophenone / PV-7)
Receptor Telemetry & Mechanism of Action
Straight-chain six-carbon homologue of alpha-PVP (and chain isomer of alpha-PiHP) acting as a potent norepinephrine-dopamine reuptake inhibitor with a DAT/SERT selectivity ratio > 1,000 (0.06 at DAT and 0.06 at NET vs. 245 at SERT in comparative pyrovalerone transporter assays). Uniquely among close siblings, alpha-PHP also antagonizes human M1 and M2 muscarinic acetylcholine receptors, intensifying xerostomia (dry mouth), tachycardia, urinary difficulty, and delirium risk at heavy exposures.
Biotransformation & Active Metabolites
Human urinary studies identify 11 Phase I and 5 Phase II metabolites dominated by dihydroxy-pyrrolidinyl-alpha-PHP (M5, 45.1%) and dihydro-alpha-PHP (M1, 25.5%). WHO 42nd ECDD highlights an extended half-life contributing to long-lasting psychotic symptoms; confirmed to cross the placenta.
Temporal Pharmacokinetics
Powerful, forced catecholaminergic stimulation with full-body mood-elevating tingling, narrow task fixation, topical mouth/nasal numbing, and a slightly less sharp initial rush than alpha-PVP paired with a longer wakefulness tail.
- Onset 2–20 minutes oral
- Peak Window 1–2.5 hours
- Total Window 2–8 hours oral
- Residual / Half-Life 1–48 hours of residual wakefulness, tachycardia, and potential long-lasting psychotic symptoms (extended half-life noted by WHO 42nd ECDD; exact numerical plasma t1/2 unverified).
Milligram potency matches alpha-PVP (common oral 10–25 mg; mucosal exposure 10–20 mg; vaporized 6–15 mg), while residual stimulation can linger up to 48 hours. repeated exposure before residual levels clear stacks sudden blood-pressure surges ('exploding heart' sensation), intense vasoconstriction, tremors, and long-lasting paranoid psychosis.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
1–5 mg oral (mucosal exposure: 2–4 mg; vaporized: 1–2 mg)
Subtle mental sharpening, alertness, and reduced drowsiness.
Mild pulse elevation and faint dry mouth.
5–10 mg oral (PMC11051472 5–15 mg; mucosal exposure: 4–10 mg; vaporized: 3–6 mg)
Strong wakefulness, narrow task focus, talkativeness, and confident mood lift.
Noticeable heart-rate increase, dry mouth, and appetite suppression.
10–25 mg oral (mucosal exposure: 10–20 mg; vaporized: 6–15 mg)
Intense mood-elevating body tingling, hyper-fixation on repetitive tasks, tactile enhancement, and strong urge to redose.
Marked tachycardia, elevated blood pressure, strong dry mouth, sweating, jaw clenching, and local mucosal numbing.
25–40 mg oral (mucosal exposure: 20–35 mg; vaporized: 15–25 mg)
Forced restlessness, hand unsteadiness, nystagmus (blurry vibrating vision), anxiety, and paranoid hyper-vigilance.
Severe peripheral vasoconstriction, sudden blood-pressure spikes, difficulty urinating, muscle spasms, and prolonged insomnia.
40+ mg oral (mucosal exposure: 35+ mg; vaporized: 25+ mg)
Long-lasting paranoid psychosis, hallucinations, agitation, delirium, or somnolent unresponsiveness.
Dangerous hypertension, cardiac arrest, hyperthermia, rhabdomyolysis, seizures, and intrauterine fetal asphyxia in pregnancy.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Potent DAT/NET blockade combined with MAO inhibition causes fatal hypertensive crisis, stroke, and hyperthermia.
Synergistic vasoconstriction, muscarinic-antagonist tachycardia, malignant hypertension, and cardiac arrest.
Tramadol induces seizures; co-consumed opiates (detected in 60% of a 29-case clinical/forensic alpha-PHP series) cause severe poly-intoxication and respiratory arrest.
Elevated Hazard — Avoid
Compounds alpha-PHP's intrinsic M1/M2 muscarinic antagonism, worsening tachycardia, hyperthermia, urinary retention, and delirium.
Masks depressant intoxication, accelerates severe dehydration, and increases collapse risk; strictly contraindicated in pregnancy.
Caution / Receptor Attenuation
Frequently precipitates acute paranoia, racing pulse, and hallucinations during alpha-PHP's long offset.
Intensifies tremors, palpitations, and restless leg symptoms.
Structural Isomer & Sibling Comparison
alpha-PHP (PV-7) is the straight-chain 6-carbon homologue of alpha-PVP and positional chain isomer of alpha-PiHP. PsychonautWiki notes alpha-PHP is slightly less aggressively stimulating at onset than alpha-PVP while sharing identical oral milligram brackets (10–25 mg common), lasting longer (2–8 h vs. 2–6 h) with a longer residual tail (up to 48 h) and extra M1/M2 muscarinic dry-mouth/urinary effects. Compared to alpha-PiHP, alpha-PHP is longer-acting (2–8 h vs. 2–5 h).
Physicochemical Stability & Storage
Form: Transparent to whitish or pale yellowish crystals, or beige/off-white crystalline powder (HCl salt) with a bitter taste and topical mucosal numbing. · Soluble in water/PBS, ethanol, methanol, DMF, and DMSO.
Store sealed in an airtight, light-protected container in a cool, dry place.
Cross-Tolerance & Dependence Profile
Very high abuse and psychological dependence liability; rapid tolerance within a single session and full cross-tolerance with alpha-PVP, alpha-PiHP, MDPHP, Hexen, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).
Chemical Architecture & Structural Profile
α-PHP (1-phenyl-2-pyrrolidin-1-ylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C16H23NO and a molar mass of 245.36 g/mol. The parent molecule is indexed under CAS registry number 13415-86-6 and in the NCBI PubChem database as CID 102107923 (Standard InChIKey: KYIJLDDXQWBNGX-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PHP is indexed within the Cathinone, Substituted cathinones, Substituted pyrrolidines structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): highly addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Gesetze im Internet — Neue-psychoaktive-Stoffe-Gesetz (NpSG) & BtMG — Bundesministerium der Justiz (2026-11-12)